Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials
QVM149 is a combination of indacaterol acetate, glycopyrronium bromide and mometasone furoate, which was delivered with the dose-confirming BreezhalerIGB gas pipeline inhalation device during the mid-stage trials. The